News und Analysen
ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual
Premier, Inc. Announces Participation in J.P. Morgan Healthcare Conference and Date and Time for Fiscal 2022 Second-Quarter Earnings Release and Conference Call
Premier, Inc. (NASDAQ: PINC) today announced that members of its management team will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. The conference is a
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive
Acadia Healthcare Announces Acquisition of CenterPointe Behavioral Health System
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the Company has completed the acquisition of CenterPointe Behavioral Health System, the largest dedicated behavioral healthcare
DGAP-News: Evotec erhält 7,5 Mio. € Förderung für Entwicklung eines COVID-19 Medikaments
DGAP-News: Evotec receives € 7.5 m grant for development of COVID-19 therapeutic
AMN Survey: Respiratory Therapists Top List of Most In-Demand Temporary Allied Healthcare Professionals
Respiratory therapists, who are essential to treating COVID-19 patients, top the list of most in-demand temporary allied healthcare professionals, according to a new survey by AMN Healthcare, the
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with
Acadia Healthcare Expands Footprint in Illinois Through Real Estate Purchase and Establishes New Behavioral Healthcare System Named Montrose Behavioral Health Hospital
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has completed the acquisition of the real estate for three currently non-operational facilities, including one adult hospital
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005059/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Acadia Healthcare Forms Joint Venture with Fairview Health Services
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Fairview Health Services, one of Minnesota’s leading health systems. Through this partnership
Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases
Gerresheimer AG: Gerresheimer schließt Vereinbarung mit bekanntem US-BioTech Unternehmen zur Entwicklung einer innovativen Pumpe ab
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005992/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
DGAP-News: Evotec receives US$ 18 m grant for women's health
DGAP-News: Evotec erhält 18 Mio. US$ Förderung im Bereich Frauengesundheit
Acadia Healthcare Forms Joint Venture With SCL Health to Build a New Behavioral Health Facility in Denver Metro Area
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with SCL Health, one of Colorado’s premier healthcare systems. The new partnership will build a new
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-News: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult